Randomized controlled trials in schizophrenia: a critical perspective on the literature

被引:43
作者
Gilbody, S [1 ]
Wahlbeck, K
Adams, C
机构
[1] Univ Leeds, Acad Unit Psychiat & Behav Sci, Cochrane Schizophrenia Grp, Leeds, W Yorkshire, England
[2] Univ Helsinki, Dept Psychiat, Cochrane Schizophrenia Grp, Lappviksvagen, Finland
[3] Cochrane Schizophrenia Grp, Oxford, England
关键词
randomized controlled trial; methodological bias;
D O I
10.1034/j.1600-0447.2002.00242.x
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Objective: The randomized trial provides an opportunity to minimize the inclusion of biases in the evaluation of interventions in psychiatry. Difficulties arise, however, when applying their results to 'real world' clinical practice and decision-making. We, therefore, examined the real world applicability of schizophrenia trials. Method: A narrative overview of the content and quality of the randomized trials relevant to the care of those with schizophrenia is provided. Results: Complex, explanatory, under-powered randomized drug trials dominate evaluative research in schizophrenia. Conclusion: Explanatory designs are a necessary but insufficient step in establishing the true worth of interventions in schizophrenia. Research from other spheres of mental health and wider health care suggest that pragmatic trials are feasible. This design allows large scale trials to be conducted which include patients which we would recognize from routine practice and which record outcomes which are of genuine interest to decision-makers.
引用
收藏
页码:243 / 251
页数:9
相关论文
共 52 条
[1]  
ADAMS CE, 1999, SCH TRIALS M 1999 ST
[2]  
ADAMS CE, 2000, COCHRANE SCHIZOPHREN
[3]  
[Anonymous], 1964, ARCH GEN PSYCHIAT, V10, P246
[4]  
[Anonymous], 1948, BMJ, V2, P769, DOI [10.1136/bmj.2.4582.769, DOI 10.1136/BMJ.2.4582.769]
[5]  
[Anonymous], 1972, PUBLIC HEALTH, DOI [DOI 10.1016/S0033-3506(02)00027-6, DOI 10.1016/S0033-3506(73)80082-4]
[6]  
Black N, 1996, BRIT MED J, V312, P1215
[7]   RECRUITMENT RATES AND FACTORS AFFECTING RECRUITMENT FOR A CLINICAL-TRIAL OF A PUTATIVE ANTIPSYCHOTIC AGENT IN THE TREATMENT OF ACUTE SCHIZOPHRENIA [J].
BOWEN, J ;
HIRSCH, S .
HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, 1992, 7 (05) :337-341
[8]   THE CLINICAL CHARACTERISTICS OF SCHIZOPHRENIC-PATIENTS CONSENTING OR NOT CONSENTING TO A PLACEBO-CONTROLLED TRIAL OF ANTIPSYCHOTIC MEDICATION [J].
BOWEN, JT ;
BARNES, TRE .
HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, 1994, 9 (06) :423-433
[9]  
Britton A, 1999, J Health Serv Res Policy, V4, P112
[10]  
Casey DE, 1997, J CLIN PSYCHIAT, V58, P55